Anaphylaxis Management: Epinephrine Dosing and Biphasic Reactions
Recognizing Anaphylaxis: Updated Diagnostic Criteria
The 2024 World Allergy Organization (WAO) updated diagnostic criteria require acute onset (minutes to hours) of illness with involvement of skin/mucosal tissue AND at least one of: respiratory compromise, cardiovascular compromise, or persistent GI symptoms. Anaphylaxis can also be diagnosed when two or more organ systems are involved after exposure to a likely allergen, or when hypotension occurs after exposure to a known allergen. Serum tryptase, drawn within 1-2 hours of symptom onset and compared to a baseline level, supports the diagnosis with levels greater than 1.2 times baseline plus 2 ng/mL considered positive.
Epinephrine: Dosing, Route, and Timing
Intramuscular epinephrine into the mid-anterolateral thigh is the first-line treatment. Adult dose: 0.3-0.5 mg of 1:1,000 (1 mg/mL) concentration. Pediatric dose: 0.01 mg/kg up to 0.3 mg. Repeat dosing every 5-15 minutes as needed; approximately 12-36% of patients require a second dose. The intramuscular route achieves peak plasma levels within 8 minutes, significantly faster than subcutaneous administration (34 minutes). Autoinjectors deliver fixed doses of 0.15 mg (15-30 kg) or 0.3 mg (over 30 kg). IV epinephrine (1:10,000 dilution, 0.1 mg boluses) is reserved for refractory anaphylaxis with cardiovascular collapse in monitored settings.
Adjunctive Therapies: Evidence and Limitations
H1 antihistamines (diphenhydramine, cetirizine) relieve cutaneous symptoms but do not treat airway obstruction, hypotension, or shock and must never delay epinephrine administration. Corticosteroids (methylprednisolone 1-2 mg/kg) are commonly administered to prevent biphasic reactions, though evidence supporting this practice is limited. Glucagon 1-5 mg IV is indicated for patients on beta-blockers who are refractory to epinephrine, as it provides inotropic and chronotropic effects independent of beta-adrenergic receptors. Inhaled bronchodilators (albuterol) are adjunctive for lower airway symptoms.
Sponsored
Biphasic Reactions: Risk Factors and Observation Duration
Biphasic reactions (recurrence of symptoms after initial resolution without re-exposure) occur in 1-20% of anaphylaxis episodes, typically within 1-72 hours (median 8-10 hours). Risk factors for biphasic reactions include: severe initial presentation requiring multiple epinephrine doses, delayed initial epinephrine administration (greater than 60 minutes), wide pulse pressure on presentation, and unknown trigger. The 2024 guidelines recommend a minimum 4-hour observation period for mild-moderate anaphylaxis and 8-24 hours for severe anaphylaxis with refractory hypotension, respiratory compromise, or risk factors for biphasic reactions.
Discharge Planning and Long-Term Management
All patients must be discharged with an epinephrine autoinjector prescription (two devices), a written anaphylaxis action plan, and referral to an allergist for trigger identification and possible immunotherapy. Prescribe a 2-3 day course of oral antihistamines and consider a short prednisone course for patients with significant mucosal edema. Counsel patients on the 1-20% risk of biphasic reactions and indications for re-presenting to the emergency department.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.